Budget Pressures Are Hampering Science Efforts, FDA And NIH Heads Say
This article was originally published in The Gray Sheet
Executive Summary
The series of short-term federal budget resolutions and spending reductions are beginning to hamper scientific activities at FDA and NIH, agency heads complained last week.
You may also be interested in...
President's 2012 Budget Request Increases Device Program Funding
The Obama administration's $329 million in requested 2012 appropriations for FDA's device center would fund special projects, including a national device registry surveillance system and technologies to respond to biological and nuclear emergencies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.